WILMINGTON, Del., Feb. 27, 2020 /PRNewswire/ -- Equifund CFP,
an equity crowdfunding platform that delivers vetted, early-stage
investment opportunities, is launching a Regulation Crowdfunding
offering for Biopact Cellular Transport Inc. ("Biopact CT"), a
nanoscale biomaterials company pioneering the breakthrough MGMR
technology for intracellular delivery.
"We are extremely excited to announce the launch of a Reg-CF
offering for Biopact Cellular Transport," said Jordan Gillissie, Equifund CFP's Founder and
CEO. "It's rare that the average investor gets an opportunity to
invest in a biotech company with such great potential at this early
a stage. We're very proud Biopact CT chose us as their Regulation
CF partner and even more thrilled they're giving the general public
a chance to participate in their success."
Biopact CT is pioneering a breakthrough technology called
MGMR. MGMR is an intracellular delivery mechanism that can
transport next-generation medicines into the cell more safely,
effectively and affordably. It is backed by 77 patents
worldwide and could be instrumental in helping cell-based therapies
fight many diseases including cancer and diabetes.
"Cell-based therapies such as CAR-T are the future of medicine,"
says Kurt Swogger, Biopact Cellular
Transport's CEO, "However, many problems still need to be addressed
-- not the least of which is they are incredibly expensive. Our
MGMR technology could greatly reduce treatment cost and open the
doors to today's most promising cellular medicines for millions
of individuals who otherwise couldn't afford advanced
life-saving treatments."
The cell therapy market is expected hit $20.2 billion by 2023 according to Market
Research Future. It's one of the fastest growing areas of
medicine and has an expected compounded annual growth rate of
22.4%.
"In the past, this caliber of investment opportunity was only
available to the well-connected or the 'qualified investor.'
Equifund is changing that. Not only do we make these
previously inaccessible opportunities available to everyone, we do
so with modest entry-level commitments," said Gillissie.
Prospective investors can find more information about Biopact
Cellular Transport's investment offering, review their offering
documents and execute an investment. They can also use the
platform's communication forum to ask questions directly to Biopact
CT's management team.
To learn about the terms of the offering, please visit
https://equifundcfp.com/biopact-ct
Important Notice About Investing in Regulation CF Offerings
Investments on the Equifund CFP website are only suitable for
investors who are familiar with and willing to accept the high risk
associated with Regulation CF Offerings. Securities sold through
these types of offerings are not publicly traded and are intended
for investors who do not have a need for a liquid investment.
Companies seeking capital through Regulation CF tend to be in
earlier stages of development and have not yet been fully tested in
the public marketplace. Investing in Regulation CF offerings
requires high risk tolerance, low liquidity concerns, and long-term
commitments. Investors must be able to afford to lose their entire
investment.
You should read the Form C offering statement appearing on the
Equifund CFP offering page. It provides more information about the
company; the terms of the securities being offered and the risks
and other considerations relating to a purchase of these
securities.
About Equifund CFP (http://equifundcfp.com)
Equifund CFP is an equity crowdfunding platform that delivers
vetted, early-stage investment opportunities to accredited and
non-accredited individuals. As a full-stack platform, Equifund CFP
allows investors to discover opportunities, review offering
documents and execute an investment in a single place. Equifund CFP
is a funding portal member of FINRA.
Media Contact:
Jordan Gillissie
234977@email4pr.com
800.777.4003
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biopact-cellular-transport-launches-equity-crowdfunding-offering-on-equifund-cfp-301012422.html
SOURCE Equifund